287 related articles for article (PubMed ID: 11523405)
1. [Study of the time course of mixed chimerism by fluorescent in situ hybridization in patients with chronic myeloid leukemia after allogenic transplantation of bone marrow].
Vinogradova OA; Savchenko VG; Neverova AL; Diachenko LV; Domracheva EV; Liubimova LS; Mendeleeva LP
Ter Arkh; 2001; 73(7):26-34. PubMed ID: 11523405
[TBL] [Abstract][Full Text] [Related]
2. [Molecular cytogenetic monitoring of chimerism and minimal residual disease in patient with chronic myeloid leukemia after allogenic and syngenic bone marrow transplantation].
Vinogradova OA; Savchenko VG; Domracheva EV; Liubimova LS; Ol'shanskaia IuV; Diachenko LV; Parovichnikova EN; Mendeleeva LP; Zakharova AV
Ter Arkh; 2002; 74(7):38-44. PubMed ID: 12181833
[TBL] [Abstract][Full Text] [Related]
3. Myeloid mixed chimerism is associated with relapse in bcr-abl positive patients after unmanipulated allogeneic bone marrow transplantation for chronic myelogenous leukemia.
Román J; Serrano J; Jiménez A; Castillejo JA; Reina ML; González MG; Rodríguez MC; García I; Sánchez J; Maldonado J; Torres A
Haematologica; 2000 Feb; 85(2):173-80. PubMed ID: 10681725
[TBL] [Abstract][Full Text] [Related]
4. Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease.
DeAngelo DJ; Hochberg EP; Alyea EP; Longtine J; Lee S; Galinsky I; Parekkedon B; Ritz J; Antin JH; Stone RM; Soiffer RJ
Clin Cancer Res; 2004 Aug; 10(15):5065-71. PubMed ID: 15297408
[TBL] [Abstract][Full Text] [Related]
5. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.
Posthuma EF; Marijt EW; Barge RM; van Soest RA; Baas IO; Starrenburg CW; van Zelderen-Bhola SL; Fibbe WE; Smit WM; Willemze R; Falkenburg JH
Biol Blood Marrow Transplant; 2004 Mar; 10(3):204-12. PubMed ID: 14993886
[TBL] [Abstract][Full Text] [Related]
6. Qualitative assessment of mixed chimerism after allogeneic bone marrow transplantation with regard to leukemic relapse.
Kögler G; Hernandez A; Heyll A; Wolf HH; Wernet P
Cancer Detect Prev; 1996; 20(6):601-9. PubMed ID: 8939346
[TBL] [Abstract][Full Text] [Related]
7. Sequential molecular monitoring of chimerism in chronic myeloid leukemia patients receiving donor lymphocyte transfusion for relapse after bone marrow transplantation.
Rapanotti MC; Arcese W; Buffolino S; Iori AP; Mengarelli A; De Cuia MR; Cardillo A; Cimino G
Bone Marrow Transplant; 1997 Apr; 19(7):703-7. PubMed ID: 9156248
[TBL] [Abstract][Full Text] [Related]
8. Fluorescent in situ hybridization on flow-sorted cells as a tool for evaluating minimal residual disease or chimerism after allogenic bone marrow transplantation.
Cotteret S; Belloc F; Boiron JM; Bilhou-Nabera C; Dumain P; Boyer C; Lacombe F; Reiffers J; Bernard P
Cytometry; 1998 Oct; 34(5):216-22. PubMed ID: 9822307
[TBL] [Abstract][Full Text] [Related]
9. Detection of minimal residual disease and persistence of host-type hematopoiesis: a study in 28 patients after sex-mismatched, non-T cell-depleted allogeneic bone marrow transplantation for Philadelphia-chromosome positive chronic myelogenous leukemia.
Elmaagacli AH; Becks HW; Beelen DW; Stockova J; Bützler R; Opalka B; Schaefer UW
Bone Marrow Transplant; 1995 Dec; 16(6):823-9. PubMed ID: 8750276
[TBL] [Abstract][Full Text] [Related]
10. Detection of mixed chimerism and leukemic relapse after allogeneic bone marrow transplantation in subpopulations of leucocytes by fluorescent in situ hybridization in combination with the simultaneous immunophenotypic analysis of interphase cells.
Kögler G; Wolf HH; Heyll A; Arkesteijn G; Wernet P
Bone Marrow Transplant; 1995 Jan; 15(1):41-8. PubMed ID: 7742754
[TBL] [Abstract][Full Text] [Related]
11. Durable molecular remission in a patient with chronic myelogenous leukemia and host-derived hematopoiesis after allogeneic bone marrow transplantation.
Wakui M; Okamoto S; Ishida A; Tanosaki R; Mori T; Kawai Y; Ohshima S; Ikeda Y
Bone Marrow Transplant; 1996 Oct; 18(4):801-4. PubMed ID: 8899199
[TBL] [Abstract][Full Text] [Related]
12. Molecular basis for therapeutic decisions in chronic myeloid leukemia patients after allogeneic bone marrow transplantation.
Román J; Alvarez MA; Torres A
Haematologica; 2000 Oct; 85(10):1072-82. PubMed ID: 11025600
[TBL] [Abstract][Full Text] [Related]
13. Association with the presence of naive T cells in chronic myeloid leukemia patients after allogeneic human stem cell transplantation and the lower incidence of chronic graft-versus host disease and relapse.
Wysoczanska B; Bogunia-Kubik K; Dlubek D; Jaskula E; Sok A; Drabczak-Skrzypek D; Sedzimirska M; Lange A
Transplant Proc; 2007 Nov; 39(9):2898-901. PubMed ID: 18022011
[TBL] [Abstract][Full Text] [Related]
14. Quantitative analysis of chimerism after allogeneic stem cell transplantation by real-time polymerase chain reaction with single nucleotide polymorphisms, standard tandem repeats, and Y-chromosome-specific sequences.
Koldehoff M; Steckel NK; Hlinka M; Beelen DW; Elmaagacli AH
Am J Hematol; 2006 Oct; 81(10):735-46. PubMed ID: 16838323
[TBL] [Abstract][Full Text] [Related]
15. Preliminary results of treatment with filgrastim for relapse of leukemia and myelodysplasia after allogeneic bone marrow transplantation.
Giralt S; Escudier S; Kantarjian H; Deisseroth A; Freireich EJ; Andersson BS; O'Brien S; Andreeff M; Fisher H; Cork A
N Engl J Med; 1993 Sep; 329(11):757-61. PubMed ID: 7688862
[TBL] [Abstract][Full Text] [Related]
16. [Is leukemic transformation of donor cells possible?].
Vinogradova OA; Savchenko VG; Domracheva EV; Parovichnikova EN; Diachenko LV; Alimova GA; Mendeleeva LP; Liubimova LS; Sokolov AN; Zhelnova EI; Pokrovskaia OS
Ter Arkh; 2004; 76(7):28-34. PubMed ID: 15379124
[TBL] [Abstract][Full Text] [Related]
17. [Allogenic bone marrow transplantation in chronic myeloid leukemias].
Liubimova LS; Savchenko VG; Mendeleeva LP; Kuz'mina LA; Anukhina MV; Gribanova EO; Demidova IA; Misiurin AV; Vinogradova OA; Domracheva EV; Poreshina LP; Kut'ina RM; Shpakova AP; Matveenko AA; Kalinin NN; Gemdzhian EG
Ter Arkh; 2004; 76(7):18-24. PubMed ID: 15379122
[TBL] [Abstract][Full Text] [Related]
18. FISH analysis of native smears from bone marrow and blood for the monitoring of chimerism and clonal markers after stem cell transplantation in children.
Fuehrer M; Gerusel-Bleck M; Konstantopoulos N; Bender-Goetze C; Walther JU
Int J Mol Med; 2005 Feb; 15(2):291-7. PubMed ID: 15647846
[TBL] [Abstract][Full Text] [Related]
19. Donor chimerism does not predict response to donor lymphocyte infusion for relapsed chronic myelogenous leukemia after allogeneic hematopoietic cell transplantation.
Chiorean EG; DeFor TE; Weisdorf DJ; Blazar BR; McGlave PB; Burns LJ; Brown C; Miller JS
Biol Blood Marrow Transplant; 2004 Mar; 10(3):171-7. PubMed ID: 14993882
[TBL] [Abstract][Full Text] [Related]
20. Dynamics in chimerism of T cells and dendritic cells in relapsed CML patients and the influence on the induction of alloreactivity following donor lymphocyte infusion.
Levenga H; Woestenenk R; Schattenberg AV; Maas F; Jansen JH; Raymakers R; De Mulder PH; van de Wiel-van Kemenade E; Schaap N; de Witte T; Dolstra H
Bone Marrow Transplant; 2007 Sep; 40(6):585-92. PubMed ID: 17637687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
